BEAM Alliance
BEAM Alliance is a non-profit association founded in 2016 and headquartered in Lyon, France, serving as the pan-European coalition of approximately 69 small and medium-sized enterprises developing products to combat antimicrobial resistance, providing advocacy, policy coordination, and networking services through membership.
- Company typePrivate
- Founded2016
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BEAM Alliance does
BEAM Alliance is a non-profit association governed by French law (law of July 1, 1901), headquartered in Lyon, France, and founded in 2016. It serves as the pan-European coalition exclusively representing approximately 69 small and medium-sized enterprises (SMEs) developing products to combat antimicrobial resistance (AMR), alongside supporting organizations in the biotechnology, pharmaceutical, and medical technology sectors. The alliance operates a member-driven go-to-market model: membership is granted through an application process requiring Board approval, and members pay annual fees (not publicly disclosed) that vary by company category and size. Members are organized into AMR-focused SMEs and Associated Organizations, with access to policy monitoring, advocacy representation, networking, event discounts, and the BEAM pipeline database.
BEAM Alliance does not develop or sell commercial products in the traditional sense. Its core offerings are organized around five standing task forces (BTF-E on Evaluation, BTF-Dx on Diagnostics, BTF-Pv on Preventive Therapies, BTF-PULL on PULL incentives, and BTF-PUSH on PUSH incentives) plus the Phage-ACT taskforce founded in March 2024. Knowledge products include the annual BeAMRometer survey (a barometer of AMR SMEs), the BEAM Pipeline Database tracking member therapeutic and diagnostic products, the BEAM Reflection Papers series, and a curated Key Reports repository. The alliance's principal technical contribution is the BEAM Infection Curve (BIC), a six-way framework developed by BTF-E for characterizing antimicrobial product activity as a roadmap for improved drug evaluation.
The alliance's value proposition is collective policy advocacy: addressing the market failure in antimicrobial R&D, fragmented national AMR policies, and regulatory barriers to SME innovation. Membership is the sole revenue stream, automatically renewed annually on a calendar-year basis (January–December). The organization has achieved tangible policy outcomes, including influencing the 2024 EU pharmaceutical legislation revision to include a 12-month transferable AMR exclusivity voucher and voluntary subscription mechanism, and convening a 60+ organization coalition advocating for AMR to be a G7 public health priority.
BEAM Alliance firmographics
Firmographics- Name
- BEAM Alliance
- Legal name
- BEAM Alliance
- Website
- https://beam-alliance.eu
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BEAM Alliance is a non-profit association founded in 2016 and headquartered in Lyon, France, serving as the pan-European coalition of approximately 69 small and medium-sized enterprises developing products to combat antimicrobial resistance, providing advocacy, policy coordination, and networking services through membership.
- Ownership category
- akta.pro rank
BEAM Alliance industry classification
Industry- Product category
- Industry Association / AMR Policy Advocacy
- NAICS
- Business Associations (813910), Professional Organizations (81392), Social Advocacy Organizations (8133)
- SIC
- Services-Membership Organizations (8600)
- akta.pro primary industry
- Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)
- akta.pro secondary industry
- Technical Committees, Working Groups & Expert Panels (BPADANAB)
Keywords
Where BEAM Alliance is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
BEAM Alliance business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Membership fees: BEAM Alliance charges annual membership fees determined by the General Assembly. Fees vary based on company category and size, with pro rata temporis adjustments for partial-year subscriptions. Invoices are sent each year in March with 30-day payment terms. Membership automatically renews annually on a calendar-year basis (January to December). No refunds are issued for mid-year termination except at BEAM's sole discretion.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Full Members — SMEs developing AMR products |
| Subscription | Annual | Associated Organizations — supporting companies and institutions |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels8 records
BEAM Alliance product offering
Product offeringCore offering
BEAM Alliance is a non-profit industry association that provides collective policy advocacy, regulatory monitoring, networking, and knowledge-sharing services for its SME members active in antimicrobial resistance (AMR) product development. It runs member task forces on PULL/PUSH incentives, diagnostics, prevention, evaluation, and phage therapy; publishes the annual BeAMRometer survey and reflection papers; maintains the BEAM Pipeline Database of member products; and engages EU and Member State policymakers on legislation such as the 2024 EU pharmaceutical revision.
Product overview
BEAM Alliance is a European industry association (governed by French law of July 1, 1901) representing Small and Medium Enterprises innovating against Antimicrobial Resistance (AMR). Founded in 2016 and headquartered in Lyon, France, BEAM Alliance does not develop or sell commercial products. Instead, it provides advocacy, policy coordination, networking, and knowledge-sharing services for its member companies. The organization focuses on driving innovation in AMR prevention, diagnostics, and therapeutics through collective advocacy efforts, including publishing the annual BeAMRometer survey, facilitating policy discussions on PULL and PUSH incentives, and maintaining a pipeline database of member company AMR products under development.
Differentiator
Problem solved
Functional benefit
Products and services
- BeAMRometer (SMEs Barometer) Annual survey report that captures the state of innovative SMEs in the AMR field, highlighting the difficult market situation and member perceptions of the AMR innovation environment.
- BEAM Pipeline Database
Quantifiable outcome
- EU pharmaceutical legislation revised to include a 12-month transferable AMR exclusivity voucher and voluntary subscription mechanism for Member States
- +2 more outcomes
Companies that use BEAM Alliance
Customer profileSegments4 records
Ideal customer profiles3 records
BEAM Alliance technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
BEAM Alliance partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- ESCMID (European Society of Clinical Microbiology and Infectious Diseases)coreESCMID Global is the world's premier meeting in Clinical Microbiology and Infectious Diseases (April 17-21, 2026, Munich). BEAM Alliance collaborates with ESCMID, with BioVersys presenting data at the conference and BEAM's CEO participating in sessions on funding and policy priorities shaping AMR innovation.
- Shionogi & Co., Ltd.majorBioVersys entered a global research collaboration and exclusive license option agreement with Shionogi for the BV500 non-tuberculosis mycobacteria (NTM) program. Shionogi is listed as a signatory of the G7 AMR coalition. BioVersys is a BEAM Alliance Full Member.
- Phage-ACT (Phage Action Collaborative Taskforce)corePhage-ACT (Phage Action Collaborative Taskforce) was founded by BEAM Alliance in March 2024 to advance phage therapy and phage-derived products. It brings together academia, biotech, government, and healthcare organizations to align regulatory frameworks, establish flexible platform-based approaches, define IVD pathways, promote innovative trial designs, and align phage therapies with market access pathways.
- ecraid (European Clinical Research Alliance on Infectious Diseases)coreecraid is a BEAM Alliance Associated Organization developing and conducting clinical studies on infectious diseases. Listed as a key partner for AMR innovation infrastructure.
- Microbiology SocietyminorThe Microbiology Society co-organized the Therapeutics and Antimicrobial Resistance (AMR) meeting on 25 June 2026 in Manchester. BEAM Alliance promoted this event to its community.
- Institut Pasteur LilleminorInstitut Pasteur Lille is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. The coalition included BEAM Alliance, IFPMA, EFPIA, Cancer Patients Europe, and over 60 leading AMR experts.
- IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)minorIFPMA is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. James Anderson, IFPMA's Director General R&D & Innovation, chairs the AMR Industry Alliance Board.
- EFPIA (European Federation of Pharmaceutical Industries and Associations)minorEFPIA is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. Kristine Peers, EFPIA's Executive Director for Legal Affairs, is listed as a signatory.
- Cancer Patients EuropeminorCancer Patients Europe (CPO) is a founding signatory of the >60-organization coalition calling on G7 leaders to address AMR. CEO Antonella Cardone is quoted emphasizing that AMR threatens cancer patient outcomes.
Scale indicators7 records
Recent moves5 records
Expansion highlights5 records
BEAM Alliance competitors and assessment
Company assessmentBroad incumbents
- IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): Global pharmaceutical industry federation that hosts the AMR Industry Alliance and engages on AMR policy. Comparable as an industry federation with AMR policy positions, but operates at a much broader pharma-industry level rather than an SME-focused coalition.
- BIO (Biotechnology Innovation Organization): Largest US biotech industry association representing member companies across therapeutic areas including AMR. Comparable as an industry-association policy advocate for biotech SMEs, but operates at a much broader scale and US-centric scope than BEAM's pan-European AMR focus.
- EFPIA (European Federation of Pharmaceutical Industries and Associations): The principal European pharmaceutical industry federation, representing large-pharma members including those working on AMR. Comparable as an EU policy advocacy organization for pharma, but EFPIA operates as a broader industry association with AMR as one of many topics — making it a broader incumbent whose AMR positions BEAM must navigate.
Direct peers
- CARB-X: Public-private partnership funding early-stage antibacterial R&D (therapeutics, diagnostics, prevention) with a ~€480M portfolio. Directly comparable as a core AMR ecosystem player; CARB-X is a key funding pathway listed on BEAM's funding page and a Coalition co-signatory.
- ReAct: International independent network advocating for action on antibiotic resistance, working with civil society, governments, and researchers. Directly comparable as an AMR-focused advocacy coalition with a global footprint, contrasting with BEAM's European SME-industry focus.
- AMR Action Fund: The world's largest VC fund dedicated exclusively to antimicrobial therapeutics and diagnostics, backed by major pharma. Directly comparable to BEAM Alliance as a focused AMR innovation catalyst — both address the broken antimicrobial market through coordinated action, though AMR Action Fund deploys capital while BEAM deploys policy advocacy.
- Antibiotic Resistance Coalition (ARC): Civil-society coalition working on antibiotic resistance policy and access. Directly comparable as a multi-stakeholder AMR advocacy coalition, though more public-interest and access-focused than BEAM's SME-industry positioning.
- AMR Industry Alliance: Industry-led coalition of pharma, biotech, diagnostics, and generics companies committed to addressing AMR. Directly comparable as an AMR-focused advocacy coalition, though its membership skews toward large-pharma signatories versus BEAM's SME-only focus.
- GARDP (Global Antibiotic Research & Development Partnership): Non-profit drug developer focused on new antibiotics for public health priorities; a BEAM Associated Organization member. Directly comparable in mission (sustaining antibiotic R&D against market failure) but operates as a product developer rather than a coalition advocate, making GARDP a peer rather than a competitor.
Emerging players
- AMR Centre (UK): UK-based translational AMR R&D initiative supporting SMEs and academics to advance antimicrobial candidates toward the clinic. Comparable as a sector-specialized AMR support organization focused on SMEs, but with a national UK scope rather than BEAM's pan-European advocacy mandate.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
BEAM Alliance social profiles
Digital presenceBEAM Alliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
BEAM Alliance leadership team
Management profileNumber of profiles
Profiles10 records
BEAM Alliance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BEAM Alliance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BEAM Alliance
What does BEAM Alliance do?
BEAM Alliance is a non-profit industry association that provides collective policy advocacy, regulatory monitoring, networking, and knowledge-sharing services for its SME members active in antimicrobial resistance (AMR) product development. It runs member task forces on PULL/PUSH incentives, diagnostics, prevention, evaluation, and phage therapy; publishes the annual BeAMRometer survey and reflection papers; maintains the BEAM Pipeline Database of member products; and engages EU and Member State policymakers on legislation such as the 2024 EU pharmaceutical revision.
Is BEAM Alliance a public or private company?
BEAM Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was BEAM Alliance founded?
BEAM Alliance was founded in 2016. It employs 11 to 50 people.
Where is BEAM Alliance based?
BEAM Alliance is headquartered in Paris, France, in the Europe region.
How does BEAM Alliance make money?
One revenue line is on record: membership fees.
Who are BEAM Alliance's main competitors?
Broad incumbents on record are IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), BIO (Biotechnology Innovation Organization) and EFPIA (European Federation of Pharmaceutical Industries and Associations). Direct peers are CARB-X, ReAct, AMR Action Fund, Antibiotic Resistance Coalition (ARC), AMR Industry Alliance and GARDP (Global Antibiotic Research & Development Partnership). AMR Centre (UK) is listed as an emerging player.
Does BEAM Alliance have an API?
No public API is recorded for BEAM Alliance.
What industry is BEAM Alliance in?
BEAM Alliance's product category is Industry Association / AMR Policy Advocacy. Its primary akta.pro industry code is BPADANAJ, Health, Pharmaceuticals & Medical Devices Regulatory Cooperation, with a secondary code of BPADANAB, Technical Committees, Working Groups & Expert Panels. Its NAICS code is 813910 and its SIC code is 8600.